{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T07:52:07Z","timestamp":1758959527370},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The postoperative management of men with lymph node involved prostate cancer (pN+) remains a challenge as there is a general lack of randomized trial data and a range of management strategies. Retrospective studies suggest a variable clinic course for patients with pN+ prostate cancer. Some men progress rapidly to metastatic disease despite further therapies, whereas other men can have a period of prolonged quiescence without adjuvant androgen deprivation therapy (ADT) or radiation therapy (RT). For men who have undergone radical prostatectomy, randomized trial data indicate that the addition of ADT in pN+ disease extends metastasis-free, prostate cancer\u2013specific, and overall survival. Additional retrospective studies suggest that adding RT is potentially beneficial in this setting, improving overall and cancer-specific survival especially in men with certain pathologic parameters. Conversely, men with lower disease burden in their lymph nodes have longer times to progression and may be candidates for observation and salvage therapy as opposed to adjuvant ADT\/RT.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000426","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:03:19Z","timestamp":1579892599000},"page":"58-63","source":"Crossref","is-referenced-by-count":2,"title":["Pathologically Node-Positive Prostate Cancer"],"prefix":"10.1097","volume":"26","author":[{"given":"Kevin B.","family":"Ginsburg","sequence":"first","affiliation":[{"name":"Department of Urology, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Cher","sequence":"additional","affiliation":[{"name":"Department of Urology, Wayne State University School of Medicine, Detroit, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kutikov","sequence":"additional","affiliation":[{"name":"Division of Urology and Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan Medical School, Ann Arbor, MI."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.juro.2017.12.048","article-title":"Contemporary incidence and outcomes of prostate cancer lymph node metastases","volume":"199","year":"2018","journal-title":"J Urol"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice\u2014stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","year":"2012","journal-title":"Trials"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2014.01.008","article-title":"The impact of definitive local therapy for lymph node\u2013positive prostate cancer: a population-based study","volume":"88","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","article-title":"Survival benefit of radical prostatectomy in lymph node\u2013positive patients with prostate cancer","volume":"57","year":"2010","journal-title":"Eur Urol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.juro.2017.01.063","article-title":"Impact of radical prostatectomy on long-term oncologic outcomes in a matched cohort of men with pathological node positive prostate cancer managed by castration","volume":"198","year":"2017","journal-title":"J Urol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1464-410X.2010.09730.x","article-title":"Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study","volume":"107","year":"2011","journal-title":"BJU Int"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/01.ju.0000139886.25848.4a","article-title":"Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup","volume":"172","year":"2004","journal-title":"J Urol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/pros.22702","article-title":"Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: the Johns Hopkins Hospital 30-year experience","volume":"73","year":"2013","journal-title":"Prostate"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1097\/01.ju.0000143448.04161.cc","article-title":"Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results","volume":"172","year":"2004","journal-title":"J Urol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.juro.2013.11.029","article-title":"Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure","volume":"191","year":"2014","journal-title":"J Urol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2013.03.053","article-title":"Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy","volume":"65","year":"2014","journal-title":"Eur Urol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","year":"2006","journal-title":"Lancet Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/S0022-5347(01)63235-X","article-title":"Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study","volume":"159","year":"1998","journal-title":"J Urol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.juro.2006.03.092","article-title":"Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone","volume":"176","year":"2006","journal-title":"J Urol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial radiation therapy oncology group 85-31","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2007.14.2042","article-title":"Role of androgen deprivation therapy for node-positive prostate cancer","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"529 e15","DOI":"10.1016\/j.urolonc.2016.06.017","article-title":"Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer","volume":"34","year":"2016","journal-title":"Urol Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2011.02.024","article-title":"Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis","volume":"59","year":"2011","journal-title":"Eur Urol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0090-4295(01)01168-2","article-title":"Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer","volume":"58","year":"2001","journal-title":"Urology"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/cncr.30373","article-title":"The role of adjuvant radiotherapy in pathologically lymph node\u2013positive prostate cancer","volume":"123","year":"2017","journal-title":"Cancer"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","article-title":"Survival outcomes of men with lymph node\u2013positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies","volume":"73","year":"2018","journal-title":"Eur Urol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2014.05.011","article-title":"More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer","volume":"67","year":"2015","journal-title":"Eur Urol"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/bju.12079","article-title":"Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy","volume":"111","year":"2013","journal-title":"BJU Int"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13679","article-title":"Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy","volume":"119","year":"2017","journal-title":"BJU Int"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.juro.2017.11.136","article-title":"Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis","volume":"199","year":"2018","journal-title":"J Urol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/phar.2168","article-title":"Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer","volume":"38","year":"2018","journal-title":"Pharmacotherapy"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urology.2017.11.055","article-title":"Association of androgen deprivation therapy and thromboembolic events: a systematic review and meta-analysis","volume":"114","year":"2018","journal-title":"Urology"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","article-title":"Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial","volume":"296","year":"2006","journal-title":"JAMA"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","article-title":"Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02\/AUO AP 09\/95","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.eururo.2015.12.010","article-title":"The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients","volume":"69","year":"2016","journal-title":"Eur Urol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.7150\/jca.29714","article-title":"Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients","volume":"10","year":"2019","journal-title":"J Cancer"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/01.ju.0000049032.38743.c7","article-title":"Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?","volume":"169","year":"2003","journal-title":"J Urol"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2008.09.043","article-title":"Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy","volume":"55","year":"2009","journal-title":"Eur Urol"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.juro.2015.12.074","article-title":"Risk stratification of pN+ prostate cancer after radical prostatectomy from a large single institutional series with long-term followup","volume":"195","year":"2016","journal-title":"J Urol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.juro.2012.10.027","article-title":"Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer","volume":"189","year":"2013","journal-title":"J Urol"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2016.06.011","article-title":"The outcome for patients with pathologic node-positive prostate cancer treated with intensity modulated radiation therapy and androgen deprivation therapy: a case-matched analysis of pN1 and pN0 patients","volume":"96","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"110625","DOI":"10.18632\/oncotarget.22610","article-title":"Lymph node ratio determines the benefit of adjuvant radiotherapy in pathologically 3 or less lymph node\u2013positive prostate cancer after radical prostatectomy: a population-based analysis with propensity-score matching","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection","volume":"74","year":"2018","journal-title":"Eur Urol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","article-title":"Initial experience of (68)Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy","volume":"69","year":"2016","journal-title":"Eur Urol"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","year":"2016","journal-title":"J Urol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bju.13540","article-title":"Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography for preoperative lymph node staging in prostate cancer","volume":"119","year":"2017","journal-title":"BJU Int"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid (6)(8)Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","article-title":"68Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer","volume":"70","year":"2016","journal-title":"Eur Urol"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of (68)Ga-PSMA PET on the Management of Patients with prostate cancer: a systematic review and meta-analysis","volume":"74","year":"2018","journal-title":"Eur Urol"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","article-title":"Impact of (68)Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology","volume":"37","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:18:35Z","timestamp":1695532715000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000426"}},"subtitle":["Casting for Cure When the Die Is Cast?"],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000426","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}